VREX

Based on Varex Imaging Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Varex Imaging do?

Varex Imaging designs and manufactures X-ray imaging components across two segments. The Medical segment supplies X-ray tubes, digital detectors, and related software for clinical imaging applications. The Industrial segment produces accelerators and detectors used in airport security, cargo screening, and nondestructive testing.

Does VREX pay dividends?

Varex Imaging does not currently pay a dividend. The company does not have a history of shareholder distributions, and its current financial profile suggests capital is allocated toward operations rather than income payouts. VREX is not suitable for dividend-focused investors at this time.

When does VREX report earnings?

Varex Imaging follows a standard quarterly earnings cadence for US-listed companies. Specific upcoming report dates are not covered by our data source. Check Varex Imaging's investor relations page for the most current schedule.

Is VREX a good stock to buy?

UQS Score rates VREX as Poor, driven by Weak ratings across Quality, Moat, Growth, and Risk pillars. The Valuation pillar is rated Good, which may reflect the market pricing in existing challenges. Investors should weigh the full pillar breakdown before drawing conclusions.

Is VREX overvalued?

The UQS Valuation pillar for VREX is rated Good, suggesting the stock is not considered expensive relative to its fundamentals at current levels. However, a favorable valuation alone does not offset the Weak ratings across other pillars. Full metrics are available to Pro members.

How does VREX compare to its competitors?

Varex Imaging's small-cap peers in the healthcare space — including Pacific Biosciences, Orthofix Medical, and NeuroPace — each operate in distinct niches. VREX's differentiation lies in X-ray component manufacturing for both clinical and industrial markets, though its overall UQS profile rates below average compared to higher-scoring healthcare names.

What is VREX's market cap bracket?

Varex Imaging is classified as a small-cap company. Small-cap stocks can offer niche market exposure but often carry higher volatility and liquidity risk compared to large- or mega-cap peers in the healthcare sector.

Who founded Varex Imaging?

Varex Imaging was established in 2017 as a spin-off from Varian Medical Systems. Detailed founding leadership information is publicly available through the company's official filings and investor relations materials.

Is VREX a long-term quality investment?

As a long-term quality indicator, VREX's Poor UQS Score — with Weak ratings across Quality, Moat, Growth, and Risk — raises meaningful questions about durability of returns over time. The Good Valuation rating is a positive signal, but sustained long-term quality typically requires strength across multiple pillars.

What is the main competitive advantage of Varex Imaging?

Varex Imaging's primary positioning comes from its specialized expertise in X-ray component manufacturing and its established OEM relationships in both medical and industrial markets. However, the UQS Moat pillar is rated Weak, suggesting these advantages may not be strongly defensible against competitive pressure.

What sector does VREX belong to?

Varex Imaging is classified in the Healthcare sector, specifically within medical imaging technology and industrial inspection equipment. Its dual-segment model gives it exposure to both clinical healthcare demand and industrial security infrastructure spending.

Is VREX a growth stock or value stock?

Based on UQS pillar labels, VREX does not fit neatly into either category. The Growth pillar is rated Weak, making it difficult to classify as a growth stock. The Valuation pillar is rated Good, offering some value characteristics — but the overall Poor UQS Score tempers that framing.

Varex Imaging Corporation currently shows below-average quality metrics, suggesting challenges with profitability.

Varex Imaging Corporation faces growth headwinds with declining or stagnant revenue trends.

Varex Imaging Corporation has some risk factors including moderate leverage or solvency concerns.

Varex Imaging Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.

Varex Imaging Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VREX.

The UQS (Unified Quality Score) for Varex Imaging Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Varex Imaging Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Varex Imaging Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.